ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Impact · against what's priced in

The ENZAMET trial provides clinical validation for Decipher as a predictive biomarker for chemotherapy benefit in metastatic prostate cancer. This expands the test's utility into a higher-stakes treatment decision framework, likely driving adoption and revenue growth.

VCYT+0.60

No priced-in read yet